Please use this identifier to cite or link to this item: https://doi.org/10.1038/leu.2011.346
Title: Management of treatment-emergent peripheral neuropathy in multiple myeloma
Authors: Richardson, P.G.
Delforge, M.
Beksac, M.
Wen, P.
Jongen, J.L.
Sezer, O.
Terpos, E.
Munshi, N.
Palumbo, A.
Rajkumar, S.V.
Harousseau, J.L.
Moreau, P.
Avet-Loiseau, H.
Lee, J.H.
Cavo, M.
Merlini, G.
Voorhees, P.
Chng, W.J. 
Mazumder, A.
Usmani, S.
Einsele, H.
Comenzo, R.
Orlowski, R.
Vesole, D.
Lahuerta, J.J.
Niesvizky, R.
Siegel, D.
Mateos, M.-V.
Dimopoulos, M.
Lonial, S.
Jagannath, S.
Bladé, J.
Miguel, J.S.
Morgan, G.
Anderson, K.C.
Durie, B.G.M.
Sonneveld, P.
Keywords: bortezomib
immunomodulatory drug
multiple myeloma
peripheral neuropathy
proteasome inhibitor
thalidomide
Issue Date: Apr-2012
Citation: Richardson, P.G., Delforge, M., Beksac, M., Wen, P., Jongen, J.L., Sezer, O., Terpos, E., Munshi, N., Palumbo, A., Rajkumar, S.V., Harousseau, J.L., Moreau, P., Avet-Loiseau, H., Lee, J.H., Cavo, M., Merlini, G., Voorhees, P., Chng, W.J., Mazumder, A., Usmani, S., Einsele, H., Comenzo, R., Orlowski, R., Vesole, D., Lahuerta, J.J., Niesvizky, R., Siegel, D., Mateos, M.-V., Dimopoulos, M., Lonial, S., Jagannath, S., Bladé, J., Miguel, J.S., Morgan, G., Anderson, K.C., Durie, B.G.M., Sonneveld, P. (2012-04). Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26 (4) : 595-608. ScholarBank@NUS Repository. https://doi.org/10.1038/leu.2011.346
Abstract: Peripheral neuropathy (PN) is one of the most important complications of multiple myeloma (MM) treatment. PN can be caused by MM itself, either by the effects of the monoclonal protein or in the form of radiculopathy from direct compression, and particularly by certain therapies, including bortezomib, thalidomide, vinca alkaloids and cisplatin. Clinical evaluation has shown that up to 20% of MM patients have PN at diagnosis and as many as 75% may experience treatment-emergent PN during therapy. The incidence, symptoms, reversibility, predisposing factors and etiology of treatment-emergent PN vary among MM therapies, with PN incidence also affected by the dose, schedule and combinations of potentially neurotoxic agents. Effective management of treatment-emergent PN is critical to minimize the incidence and severity of this complication, while maintaining therapeutic efficacy. Herein, the state of knowledge regarding treatment-emergent PN in MM patients and current management practices are outlined, and recommendations regarding optimal strategies for PN management during MM treatment are provided. These strategies include early and regular monitoring with neurological evaluation, with dose modification and treatment discontinuation as indicated. Areas requiring further research include the development of MM-specific, patient-focused assessment tools, pharmacogenomic analysis of patient DNA, and trials to assess the efficacy of pharmacological interventions. © 2012 Macmillan Publishers Limited All rights reserved.
Source Title: Leukemia
URI: http://scholarbank.nus.edu.sg/handle/10635/126928
ISSN: 08876924
DOI: 10.1038/leu.2011.346
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

171
checked on Jun 18, 2021

WEB OF SCIENCETM
Citations

162
checked on Jun 18, 2021

Page view(s)

200
checked on Jun 18, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.